期刊文献+

噻托溴胺粉吸入剂对稳定期COPD患者运动耐量及肺功能的疗效 被引量:12

Therapeutic effect of tiotropium bromide inhalation powder on exercise tolerance and lung function in patients with stable COPD
下载PDF
导出
摘要 目的探讨稳定期COPD患者予噻托溴胺粉吸入剂治疗后运动耐量及肺功能的改善作用。方法 60例稳定期COPD患者,随机分成治疗组、对照组以及空白对照组。观察三组治疗不同时期肺功能的变化和St Georges呼吸问卷(SGRQ)情况,进行6 min步行试验观察运动耐力的变化。结果用药6个月后治疗组患者咳嗽、咳痰、气促等症状明显好转,前后比较(P<0.05),用药6个月后治疗组FEV1、FVC、FEV1/FVC及FEV1占预计值(%)、运动耐力较对照组及空白对照组改善,三组比较差异有显著性(P<0.05)。治疗组运动耐力(6MWT)增加,SGRQ评分比较治疗组明显下降(P<0.05)。结论吸入噻托溴胺粉吸入剂对稳定期COPD患者运动耐量及肺功能有改善作用,并可以减少急性发作次数,改善患者生活质量,且副反应少。 Objective To evaluate the therapeutic effect of tiotropium bromide inhalation powder on exercise tolerance and lung function in patients with stable COPD and its possible mechanism. Methods 60 patients with stable COPD were randomly divided into treatment group, control group and blank control group. Lung function and St Georges Respiratory Questionnaire (SGRQ) were tested in three different periods of treatment. Meanwhile, exercise tolerance was observed by 6 rain walk test. Results After 6 months treatment, cough, expectoration, tachypnea and other symptoms in treatment group significantly improved, and there was significant differences be- tween before and after treatment (P 〈0. 05) , and FEVl , FVC, FEVI/FVC, FEV1 percentage of predicted value ( % ) and exercise tol- erance in treatment group significantly improved, compared with the other two groups ( P 〈0. 05 ) , as well as the SGRQ score significantly decreased compared with the other two groups (P 〈 0. 05 ). Conclusion Tiotropium bromide inhalation powder can improve the exercise tolerance and lung function in stable COPD, reduce the number of acute episodes, and improve quality of life with few side effects.
作者 米翔
出处 《临床肺科杂志》 2012年第7期1183-1185,共3页 Journal of Clinical Pulmonary Medicine
基金 广西卫生厅资助项目(11086)
关键词 肺疾病 慢性阻塞性 噻托溴胺 肺功能 pulmonary disease chronic obstructive Tiotropium lung function
  • 引文网络
  • 相关文献

参考文献5

二级参考文献34

共引文献8292

同被引文献99

  • 1柳涛,蔡柏蔷.一种新型的生活质量评估问卷:慢性阻塞性肺疾病评估测试[J].中国医学科学院学报,2010,32(2):234-238. 被引量:164
  • 2慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志(电子版),2014,6(2):67-80. 被引量:2042
  • 3肖建,杜春玲.慢性阻塞性肺疾病病因及发病机制研究进展[J].中国老年学杂志,2014,34(11):3191-3194. 被引量:166
  • 4慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8235
  • 5Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and restrictive lung disease and markers of inflammation: date from the Third National Health and Nutrition Examination. Am J Med ,2003,114: 758-762.
  • 6Tashkin DP,Celli B,Senn S,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med,2008,359:1543-1544.
  • 7Rabe K F, Fabbri L M, Israel E, et al. Effect of ADRB2 polymorphisms on the efficacy of salmeterol andtiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial [J]. Lancet Respir Med, 2014, 2(1): 44-53.
  • 8Jenkins C R. Tiotropium and the risk of death in COPD [J]. NEnglJMed, 2014, 370(5): 482-483.
  • 9Kobli:ek V. The position of tiotropium in new treatment guidelines for chronic obstructive pulmonary disease [J]. VnitrLek, 2013, 59(12): 1073-1080.
  • 10Vozzi F, Bianchi F, Ahluwalia A, et al. Hydrostatic pressure and shear stress affect endothelin-1 and nitric oxide release by endothe- lial cells in bioreactors [ J ]. Biotechnol J,2014,9 ( 1 ) : 146 - 154.

引证文献12

二级引证文献111

;
使用帮助 返回顶部